RxDoctor Payments Data

Joselito Navaleza, MD

Ophthalmology · Easton, MDNPI 1316993561

Payments from drug & device makers

$886in general payments, 2019–2025

Across 39 payments — averaging $22.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$258
  • Alcon$168
  • Glaukos Corporation$152
  • Amgen$63
  • Aerie Pharmaceuticals, Inc.$52
  • Novartis$49
  • plus $144 from 6 others

What the payments were for

  • Food & beverage$86798%
  • Gifts$192%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$886 in reported general payments places this provider in the 40th percentile of 493 ophthalmology providers in Maryland.

See all ophthalmology providers in Maryland

Medicare billing

Part B allowed, 2024
$524,644
Medicare patients
1,456
Services billed
4,696

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost92$43,528
RhopressaNetarsudil Mesylate53$28,936
Prednisolone Acetate367$17,124
RestasisCyclosporine18$17,044
CombiganBrimonidine Tartrate/Timolol37$14,210
Travoprost52$13,134
Latanoprost749$10,467
Cyclosporine17$6,042
MoxifloxacinMoxifloxacin Hcl297$5,668
Timolol Maleate377$5,555
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol32$5,382
Brimonidine Tartrate185$3,835
Brinzolamide13$3,267
Ketorolac Tromethamine232$3,132
BromsiteBromfenac Sodium12$2,870

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan$258$74,782147 claims
Aerie Pharmaceuticals, Inc.Rhopressa$52$28,93653 claims
Sun Pharmaceutical Industries Inc.Bromsite$31$2,87012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 493 ophthalmology providers in Maryland.

Other ophthalmology in Easton

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →